• Product nameAnti-FGF 23 antibody
    See all FGF 23 primary antibodies
  • Description
    Goat polyclonal to FGF 23
  • Tested applicationsSuitable for: WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide:


    , corresponding to internal sequence amino acids 176-188 of Human FGF 23

  • Positive control
    • Human Brain (Hippocampus) lysate.



Our Abpromise guarantee covers the use of ab56326 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.3 - 1 µg/ml. Detects a band of approximately 27 kDa (predicted molecular weight: 28 kDa). An additional band of unknown identity was also consistently observed at 37kDa. This band was successfully blocked by incubation with the immunising peptide.
ICC/IF Use a concentration of 1 µg/ml.


  • FunctionRegulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Upregulates EGR1 expression in the presence of KL (By similarity). Acts directly on the parathyroid to decrease PTH secretion (By similarity). Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralization.
  • Tissue specificityExpressed in osteogenic cells particularly during phases of active bone remodeling. In adult trabecular bone, expressed in osteocytes and flattened bone-lining cells (inactive osteoblasts).
  • Involvement in diseaseDefects in FGF23 are the cause of autosomal dominant hypophosphataemic rickets (ADHR) [MIM:193100]. ADHR is characterized by low serum phosphorus concentrations, rickets, osteomalacia, leg deformities, short stature, bone pain and dental abscesses.
    Defects in FGF23 are a cause of hyperphosphatemic familial tumoral calcinosis (HFTC) [MIM:211900]. HFTC is a severe autosomal recessive metabolic disorder that manifests with hyperphosphatemia and massive calcium deposits in the skin and subcutaneous tissues.
  • Sequence similaritiesBelongs to the heparin-binding growth factors family.
  • Post-translational
    Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases.
    O-glycosylated by GALT3. Glycosylation is necessary for secretion; it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23.
  • Cellular localizationSecreted. Secretion is dependent on O-glycosylation.
  • Information by UniProt
  • Database links
  • Alternative names
    • ADHR antibody
    • FGF-23 antibody
    • Fgf23 antibody
    • FGF23_HUMAN antibody
    • FGFN antibody
    • Fibroblast growth factor 23 antibody
    • Fibroblast growth factor 23 C-terminal peptide antibody
    • Fibroblast growth factor 23 precursor antibody
    • HPDR2 antibody
    • HYPF antibody
    • Phosphatonin antibody
    • PHPTC antibody
    • Tumor derived hypophosphatemia inducing factor antibody
    • Tumor-derived hypophosphatemia-inducing factor antibody
    see all

Anti-FGF 23 antibody images

  • Anti-FGF 23 antibody (ab56326) at 0.5 µg/ml + Human Brain (Hippocampus) lysate (35µg protein in RIPA buffer)

    Predicted band size : 28 kDa
    Observed band size : 27 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 37 kDa. We are unsure as to the identity of these extra bands.
  • ICC/IF image of ab56326 stained SHSY5Y cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal donkey serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab56326, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 donkey anti-goat IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

References for Anti-FGF 23 antibody (ab56326)

This product has been referenced in:
  • Uchihashi K  et al. Phosphaturic mesenchymal tumor, nonphosphaturic variant, causing fatal pulmonary metastasis. Hum Pathol 44:2614-8 (2013). Read more (PubMed: 23954138) »
  • Tang WJ  et al. Autocrine/paracrine action of vitamin D on FGF23 expression in cultured rat osteoblasts. Calcif Tissue Int 86:404-10 (2010). Read more (PubMed: 20354682) »

See all 2 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab56326.
Please use the links above to contact us or submit feedback about this product.